An immunodominant epitope of the human immunodeficiency virus envelope glycoprotein gp160 recognized by class I major histocompatibility complex molecule-restricted murine cytotoxic T lymphocytes. NLM AIDSLINE Important note: Information in this article was accurate in 1988. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


An immunodominant epitope of the human immunodeficiency virus envelope glycoprotein gp160 recognized by class I major histocompatibility complex molecule-restricted murine cytotoxic T lymphocytes.

Proc Natl Acad Sci U S A. 1988 May;85(9):3105-9. Unique Identifier : AIDSLINE MED/88203649
Takahashi H; Cohen J; Hosmalin A; Cease KB; Houghten R; Cornette JL; DeLisi C; Moss B; Germain RN; Berzofsky JA; Metabolism Branch, National Cancer Institute, Bethesda, MD 20892.


Abstract: Because cytotoxic T lymphocytes (CTL) may be important for preventing direct cell-to-cell transmission of human immunodeficiency virus (HIV), the agent responsible for acquired immunodeficiency syndrome, we have begun to investigate the epitope specificity and immune response (Ir) gene control of anti-HIV CTL responses in experimental animals. Mice were infected with a recombinant vaccinia virus expressing the HIV gp160 envelope gene, and the primed lymphocytes were restimulated in vitro with a transfected histocompatible cell line expressing the same gene. Our results show that H-2d mice are CTL high responders and H-2k mice are low responders to the HIV gp160 envelope protein under these conditions. Moreover, the H-2d mice respond predominantly to a single immunodominant site represented by a 15-residue synthetic peptide conforming to the amphipathic alpha-helix model of T-cell epitopes and seen by CD4- CD8+ CTL in association with the Dd class I major histocompatibility complex (MHC) molecules. The facts that CTL responses were detected in the context of only one of four class I MHC molecules tested and that the response was limited predominantly to a single epitope indicate that the CTL repertoire elicited by the HIV envelope protein in association with murine class I MHC molecules may be very limited. In addition, this epitope occurs in a highly variable segment of the envelope protein. This puts constraints on the use of a single peptide sequence from this region in a vaccine, as such a vaccine would have to be polyvalent. Nevertheless, this same variability suggests that this region may be under selective pressure from human CTL, and therefore that this site may be immunodominant in humans as well as mice and so of clinical importance in vaccine development.
Keywords: Acquired Immunodeficiency Syndrome/GENETICS/IMMUNOLOGY Animal Epitopes/*IMMUNOLOGY Genes, MHC Class II H-2 Antigens/ANALYSIS/IMMUNOLOGY HIV/*IMMUNOLOGY HLA Antigens/*IMMUNOLOGY Mice Mice, Inbred BALB C Mice, Inbred C3H Phenotype Retroviridae Proteins/*IMMUNOLOGY Support, Non-U.S. Gov't Support, U.S. Gov't, Non-P.H.S. T-Lymphocytes, Cytotoxic/*IMMUNOLOGY Transfection Viral Envelope Proteins/*IMMUNOLOGY JOURNAL ARTICLE

KWDacquiredimmunodeficiencysyndrome/genetics/immunologyanimalepitopes/KWDimmunologygenes,mhcclassiih-2antigens/analysis/immunologyhiv/KWDimmunologyhlaantigens/KWDimmunologymicemice,inbredbalbcmice,inbredc3hphenotyperetroviridaeproteins/KWDimmunologysupport,non-uKWDsKWDgov'tsupport,uKWDsKWDgov't,non-pKWDhKWDsKWDt-lymphocytes,cytotoxic/KWDimmunologytransfectionviralenvelopeproteins/KWDimmunologyjournalarticle
880830
M8880013


Copyright © 1988 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1988. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1988. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .